The U.S. Food and Drug Administration has approved Merck's Keytruda (pembrolizumab) plus chemotherapy as treatment for adult patients with primary advanced or recurrent endometrial carcinoma. This is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results